Literature DB >> 1952427

Glucocorticoid resistance in chronic asthma. Peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A.

C J Corrigan1, P H Brown, N C Barnes, J J Tsai, A J Frew, A B Kay.   

Abstract

A total of 37 chronic severe asthmatic patients with documented reversible airways obstruction were classified as glucocorticoid sensitive or resistant according to changes in the FEV1 following a course of oral prednisolone. The phenotype and expression of activation molecules on peripheral blood T lymphocytes from these patients just before the course of prednisolone were studied using flow cytometry. The resistant patients had significantly elevated percentages of T lymphocytes expressing the activation molecules IL-2R and HLA-DR compared to the sensitive patients. There were no differences between the patient groups in the percentages of peripheral blood T lymphocytes expressing the phenotypic markers CD4 and CD8. Peripheral blood mononuclear cells (PBMC) from 29 patients were cultured in vitro with the T lymphocyte mitogen PHA in the presence or absence of dexamethasone or cyclosporin A. Dexamethasone (10(-7) mol/L) significantly inhibited the proliferation of T lymphocytes from the sensitive but not the resistant asthmatic subjects. In contrast, cyclosporin A (500 ng/ml) inhibited proliferation of T lymphocytes from both the sensitive and the resistant asthmatic subjects, although the effect was less marked in the latter group. Inhibition of elaboration of interleukin-2 and interferon-gamma by mitogen-stimulated T lymphocytes from sensitive and resistant asthmatic patients was also studied. Dexamethasone (10(-7) mol/L) significantly inhibited the production of interleukin-2 and interferon-gamma by proliferating T lymphocytes isolated from the glucocorticoid-sensitive but not the resistant chronic asthmatic patients. Cyclosporin A (500 ng/ml) inhibited the elaboration of both lymphokines by T lymphocytes derived from both patient groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952427     DOI: 10.1164/ajrccm/144.5.page

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  21 in total

Review 1.  Glucocorticoid-resistant asthma.

Authors:  Tuck-Kay Loke; Ana R Sousa; Christopher J Corrigan; Tak H Lee
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

Review 2.  Recent advances in asthma.

Authors:  P J Barnes; T H Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

Review 3.  The melatonin-cytokine connection in rheumatoid arthritis.

Authors:  M Cutolo; G J M Maestroni
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

Review 4.  Clinical pharmacology of asthma. Implications for treatment.

Authors:  A J Frew; S T Holgate
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 5.  Immunosuppressive agents and asthma.

Authors:  T Fukuda
Journal:  Clin Rev Allergy       Date:  1994

6.  IL-2 and IL-4 counteract budesonide inhibition of GM-CSF and IL-10, but not of IL-8, IL-12 or TNF-alpha production by human mononuclear blood cells.

Authors:  S Larsson; C G Löfdahl; M Linden
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

7.  The use of cyclosporin in corticosteroid dependent asthma.

Authors:  M E Coren; M Rosenthal; A Bush
Journal:  Arch Dis Child       Date:  1997-12       Impact factor: 3.791

Review 8.  Regulation of allergic airways inflammation by cytokines and glucocorticoids.

Authors:  L Cameron; Q Hamid
Journal:  Curr Allergy Asthma Rep       Date:  2001-03       Impact factor: 4.806

Review 9.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

10.  Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy.

Authors:  E R Sher; D Y Leung; W Surs; J C Kam; G Zieg; A K Kamada; S J Szefler
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.